ENTRY       D11338                      Drug
NAME        Loncastuximab tesirine (USAN);
            Loncastuximab tesirine-lpyl;
            Zynlonta (TN)
PRODUCT     ZYNLONTA (ADC Therapeutics America)
FORMULA     C6544H10048N1718O2064S52
EXACT_MASS  147387.9585
MOL_WEIGHT  147479.4541
REMARK      ATC code: L01FX22
            Product: D11338<US>
EFFICACY    Antineoplasitc, Anti-CD19 antibody
  DISEASE   Diffuse large B-cell lymphoma not otherwise specified [DS:H02434]
  TYPE      Antibody-drug conjugate
COMMENT     Treatment of hematological cancers
TARGET      CD19 [HSA:930] [KO:K06465]
  PATHWAY   hsa04151(930)  PI3K-Akt signaling pathway
            hsa04640(930)  Hematopoietic cell lineage
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FX Other monoclonal antibodies and antibody drug conjugates
                 L01FX22 Loncastuximab tesirine
                  D11338  Loncastuximab tesirine (USAN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Loncastuximab Tesirine
                D11338  Loncastuximab tesirine (USAN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                CD19
                 D11338  Loncastuximab tesirine (USAN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11338
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11338
DBLINKS     CAS: 1879918-31-6
            PubChem: 384585316
///
